创新药又迎重磅利好！嘉实超级ETF“医药三剑客”半日涨幅均超0.5%

Group 1 - The market experienced a slight decline on the first trading day of August, with the Shanghai Composite Index down by 0.19% at midday [1] - The introduction of the "newly listed drug initial pricing mechanism" by the National Healthcare Security Administration (NHSA) has positively impacted the innovative drug sector, leading to several stocks reaching historical highs [1] - The "biological vaccine ETF" (562860), "Kechuang pharmaceutical ETF" (588700), and "Hang Seng medical ETF" (159557) all saw gains exceeding 0.5%, with the biological vaccine ETF leading the pack at 0.80% [1] Group 2 - As of July 31, the biological vaccine ETF (562860) and Kechuang pharmaceutical ETF (588700) had assets under management of 272 million and 217 million respectively, making them the largest in their respective categories [1] - Multiple institutions maintain a relatively optimistic outlook on the innovative drug market, with CITIC Securities noting that the development of innovative drugs in China has achieved significant progress [2] - Industrial trends such as "innovation + internationalization" are expected to remain core directions for the pharmaceutical sector, supported by policy initiatives and enhanced global competitiveness [2]